LAKE FOREST, Ill., July 2 /PRNewswire/ -- Bioniche Pharma, a leading developer and manufacturer of injectable pharmaceuticals, announced today the acquisition of Baxter Healthcare Corporation's ENLON product line, including:-- ENLON® (edrophonium chloride injection, USP) 10 mg/mL, 15 mL vial -- ENLON-PLUS® (edrophonium chloride, USP and atropine sulfate, USP) Injection 5 mL ampule -- ENLON-PLUS® (edrophonium chloride, USP and atropine sulfate, USP) Injection, 15 mL Multi-dose Vial
Bioniche purchased the rights and certain assets related to the ENLON® product line from Baxter, which discontinued ENLON® in February 2008. Bioniche anticipates launching all three codes of ENLON® in October 2008.
"We are pleased to reintroduce these products, providing health care professionals with access to additional options," said Steve Thornton, CEO Bioniche Pharma.
Read More